investors & media investors press releases events & presentations in the media analyst coverage financial information stock information corporate governance investor faqs information request contact developing innovative therapies forpatients with kidney and vascular diseases proteon is developing first in class therapeutics to improvethe health of patients with kidney and vascular diseases learn more focused on vascular access failurein hemodialysis proteon is seeking to address vascular access failure a significant medical need for hemodialysis patients learn more learn more aboutinvestigational vonapanitase an investigational drug in phase 3 clinical development to improve patency after surgical creation of an arteriovenous fistula avf for hemodialysis learn more who we are proteon therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel first in class therapeutics . proteon s lead product candidate vonapanitase formerly prt 201 is an investigational drug designed to treat vessel injury response that leads to blockages in blood vessels and reduced blood flow . proteon is currently evaluating investigational vonapanitase in patency 1 and patency 2 two phase 3 clinical trials in patients with chronic kidney disease ckd undergoing surgical creation of a radiocephalic arteriovenous fistula rc avf for hemodialysis . proteon has also completed a phase 1 clinical trial in patients with symptomatic peripheral artery disease pad . learn more news view rss feed all news e mail alerts proteon therapeutics inc. 200 west street waltham ma 02451 phone 781 890 0102 fax 781 487 6729 about us overview management board of directors careers clinical development technology clinical trials clinical need clinical glossary publications investors & media investors media contact contact 2015 proteon therapeutics inc all rights reservedprivacy policy terms of use contact